Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Lymphoma, T-Cell, Peripheral
Treatment with romidepsin leads to highly durable responses in a subset of patients with relapsed/refractory PTCL, with responses ongoing as long as 48 months.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency